Therefore, pH/GSH-responsive controllable drug release at the tumor site would maximize the inhibition of cancer cell growth and decreased the off-target systemic side effects of chemotherapy, which confirms the superiority of C/M@Alb NCs as a smart vehicle for cancer therapeutics. This evidence concerns the gene ALB and neoplasm.